Allogene Therapeutics explores ALPHA3 trial potential for allogeneic CAR T in LBCL treatment

Allogene Therapeutics explores ALPHA3 trial potential for allogeneic CAR T in LBCL treatment
Allogene Therapeutics ALPHA3 trial advances

Allogene Therapeutics is advancing its research into allogeneic CAR T therapies through its ALPHA3 clinical trial, focusing on new treatment options for patients with large B-cell lymphoma (LBCL).

Dr. Zachary Roberts, the company’s Executive Vice President of R&D and Chief Medical Officer, recently detailed these developments during an interview with Endpoints News. The discussion emphasized the potential for off-the-shelf cell therapy to reshape treatment paradigms for LBCL, positioning Allogene Therapeutics at the forefront of innovation in cancer care.

Allogene previously advanced its ALPHA3 trial to evaluate allogeneic CAR T cell therapy in large B-cell lymphoma patients, according to a recent update. The company also delivered its Q1 report with a focus on progress in allogeneic CAR T development, as detailed in a corporate statement. These steps reflect the firm’s ongoing commitment to advancing cell therapies.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.